Supplementary figures and supplementary table legends from Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer
Authors: Stover Elizabeth H. , Baco Maria B. , Cohen Ofir , Li Yvonne Y. , Christie Elizabeth L. , Bagul Mukta , Goodale Amy , Lee Yenarae , Pantel Sasha , Rees Matthew G. , Wei Guo , Presser Adam G. , Gelbard Maya K. , Zhang Weiqun , Zervantonakis Ioannis K. , Bhola Patrick D. , Ryan Jeremy , Guerriero Jennifer L. , Montero Joan , Liang Felice J. , Cherniack Andrew D. , Piccioni Federica , Matulonis Ursula A. , Bowtell David D.L. , Sarosiek Kristopher A. , Letai Anthony , Garraway Levi A. , Johannessen Cory M. , Meyerson Matthew 
Published: April 2023

<p>Figure S1A. Cisplatin and paclitaxel sensitivity in ovarian cancer cell lines Figure S1B. Cell line growth curves in ORF screen Figure S1C. Candidate resistance genes scoring in {greater than or equal to}2 conditions in primary ORF screen Figure S2A. Expression of MDR1, encoded by ABCB1 Figure S2B. Overexpression of ABCB1 and paclitaxel response Figure S2C. Overexpression of ABCB1 and paclitaxel response in HGSOC cell lines Figure S2D. Effect of ABCB1 overexpression on cell growth with paclitaxel treatment Figure S2E. Effect of MDR1/P-glycoprotein inhibitor elacridar on paclitaxel response Figure S2F. Overexpression of ABCB1 and colony formation with paclitaxel treatment and effect of elacridar on colony formation Figure S3A. Cell line growth curves in mini-pool overexpression secondary screen Figure S3B. Mini-pool overexpression secondary screen Figure S3C. Top-ranked genes by LFC in mini-pool overexpression secondary screen Figure S4A. Cell line growth curves in CRISPR-Cas9 screen Figure S4B. CRISPR-Cas9 screen data from cisplatin+paclitaxel "low-dose" combination Figure S5A. Expression of BCL-XL and BCL-W Figure S5B. Overexpression of BCL2L1 (BCL-XL) or BCL2L2 (BCL-W) and paclitaxel response in HGSOC cell lines Figure S5C. Effect of overexpressing anti-apoptotic proteins on apoptotic priming Figure S5D. Expression of BCL-2 and MCL1 Figure S5E. Overexpression of BCL2 or MCL1 and apoptosis induction Figure S5F. Overexpression of BCL2 or MCL1 and paclitaxel or cisplatin response Figure S6. Cell cycle analysis of HGSOC cells overexpressing anti-apoptotic proteins Figure S7A. Genomic alterations in anti-apoptotic genes in primary ovarian cancer Figure S7B. Copy-number alterations of anti-apoptotic genes in primary HGSOC Figure S7C. Copy-number alterations of pro-apoptotic genes in primary HGSOC Figure S7D. Copy number and expression of anti-apoptotic genes in primary HGSOC Figure S7E. MCL1 and BCL2L1 are focally amplified in HGSOC Figure S7F. Progression-free interval of patients with primary HGSOC with focal amplifications of BCL2L1 or MCL1 Figure S8A. Copy number alterations of anti-apoptotic genes in ovarian cancer cell lines Figure S8B. Expression of anti-apoptotic genes in ovarian cancer cell lines Figure S9A. Expression of anti-apoptotic genes in platinum-sensitive and -resistant HGSOC Figure S9B. Expression of anti-apoptotic genes in paired platinum-sensitive and- resistant HGSOC Figure S10A. Effects of single-agent anti-apoptotic protein inhibitors on ovarian cancer cell lines Figure S10B. BH3 profiling of HGSOC cell lines with a panel of pro-apoptotic peptides</p>